top
Search terms
Results 1 - 10 of 14 - ordered by :
Pages: 1 2
Ehjournal

Abstract Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among high' global risk primary ...

European Heart Journal, Koenig, Wolfgang, Ridker, Paul M

Date : 01/01/2011 Item size : 264590 bytes
Ehjournal

Methods and results We examined the association of SAA and HDL-C with mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, which included 3310 patients undergoing coronary ...

European Heart Journal, Zewinger, Stephen, Drechsler, Christiane, Kleber, Marcus E., Dressel, Alexander, Riffel, Julia, Triem, Sarah, Lehmann, Marlene, Kopecky, Chantal, Säemann, Marcus D., ...

Date : 14/11/2015 Item size : 369028 bytes
Ehjournal

Rather, they do so to better target therapy and improve the lives of their patients. [...]when considering the use of any biomarker for cardiovascular risk prediction in primary prevention, ...

European Heart Journal, Ridker, Paul M, Kastelein, John J.P., Genest, Jacques, Koenig, Wolfgang

Date : 01/05/2013 Item size : 180317 bytes
Ehjournal

Abstract Aims Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine ...

European Heart Journal, Blankenberg, Stefan, Salomaa, Veikko, Makarova, Nataliya, Ojeda, Francisco, Wild, Philipp, Lackner, Karl J., Jørgensen, Torben, Thorand, Barbara, Peters, Annette, Nauck, ...

Date : 07/08/2016 Item size : 392256 bytes
Ehjournal

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial See page 3248 for the editorial comment on ...

European Heart Journal, Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, ...

Date : 07/12/2014 Item size : 370049 bytes
Ehjournal

Rather, they do so to better target therapy and improve the lives of their patients. [...]when considering the use of any biomarker for cardiovascular risk prediction in primary prevention, ...

European Heart Journal, Ridker, Paul M, Kastelein, John J.P., Genest, Jacques, Koenig, Wolfgang

Date : 01/05/2013 Item size : 180087 bytes
Ehjournal

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial See page 3248 for the editorial comment on ...

European Heart Journal, Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, ...

Date : 07/12/2014 Item size : 381865 bytes
Ehjournal

Abstract Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce first major cardiovascular events among high' global risk primary ...

European Heart Journal, Koenig, Wolfgang, Ridker, Paul M

Date : 01/01/2011
Ehjournal

Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up Patients ...

European Heart Journal, Lamina, Claudia, Meisinger, Christa, Heid, Iris M., Löwel, Hannelore, Rantner, Barbara, Koenig, Wolfgang, Kronenberg, Florian

Date : 01/11/2006 Item size : 267678 bytes
Ehjournal

Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease Introduction Type IIA secretory ...

European Heart Journal, Koenig, Wolfgang, Vossen, Carla Y., Mallat, Ziad, Brenner, Hermann, Benessiano, Joëlle, Rothenbacher, Dietrich

Date : 01/11/2009